Applied DNA Reports Fiscal Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Applied DNA Sciences (APDN) Misses Q3 EPS by 5c
August 6, 2020 5:28 PM EDTApplied DNA Sciences (NASDAQ: APDN) reported Q3 EPS of ($0.72), $0.05 worse than the analyst estimate of ($0.67).
We continued during the quarter to position the Company to serve the unmet and evolving needs for COVID-19 testing solutions and vaccine development, said Dr. James A. Hayward, president and CEO of Applied DNA Sciences. Upon the receipt of FDA Emergency Use Authorization (EUA) for our Linea COVID-19 diagnostic assay kit (for use with nasopharyngeal (NP) swab and anterior nasal swab (ANS) sample collections), we put into place the foundation of our COVID-19 diagnostics business: we established the requisite supply... More
